Dr. Bauml on a New Platform to Enhance Lung Cancer Clinical Trial Enrollment

Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses a novel IT platform designed to enhance lung cancer clinical trial enrollment.

Nationwide, only about 5% of patients with lung cancer enroll on a clinical trial. At academic centers, that number is slightly higher at 10%-15%. In this single-arm trial, research assistants were able to use a patient’s chart to input data regarding their stage, prior treatments, and molecular profile into a platform for clinical trials. That information, on a tablet, was given to the patient’s physician, displaying what trials the patient might be eligible for.

Prior to the visit, though, both the patient and physician filled out surveys about how they viewed clinical trials. These groups were then followed to see how many patients that were eligible for clinical trials actually enrolled. The study achieved a 40% enrollment rate.

<<<

View more from the 2015 World Conference on Lung Cancer